News

Results revealed the inner lower and inner left subfields of the better eye were more strongly associated with vision-related quality of life than the worse eye.

An analysis of more than 700 videos on TikTok reveals new insight into the levels and purveyors of misinformation in the most popular ophthalmology content on the platform.

The UCLA hepatologist discusses the current treatment landscape, prospects for improved diagnostics, and the overlap syndrome live from ACG 2023.

New data suggests retinal vein occlusion in individuals under 75 years of age correlates with increased dementia risk, while those older than 75 have a reduced risk.

Volume and frequency of alcohol consumption were associated with a greater risk of visual impairment and blindness among patients with newly diagnosed OAG.

The post-hoc analysis of a phase 3 clinical trial suggests SB15 has comparable clinical efficacy and safety to aflibercept in patients with nAMD.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.

The investigator discusses the unique interplay between conditions like IBD and gestational risks—and how specialists need to improve communication.

No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.

The FDA has issued a Class I recall for some of Fresenius Medical Care's hemodialysis machines due to potential exposure to toxic compounds, affecting eight specific models from the 2008 Series.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Patients with UC and Crohn's disease showed higher drug levels and good acceptance when switching from intravitreal to subcutaneous infliximab.

The FDA has granted 510(k) Clearance to the Omnipod 5 app for iPhone, making Insulet Corporation the first to offer a tubeless AID system with smartphone control.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.

The study author discusses the clinical implications of his team's assessment into a risk factor score for alcohol relapse among post-transplant patients with ALD.

Results from the 104-week extension study were presented at ACG 2023, demonstrating mirikizumab’s favorable safety and efficacy profiles.

Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.

Experts recommended the early use of anti-TNF therapy for patients with ulcerative colitis and Crohn disease, offering further input regarding the introduction, optimization, and maintenance of the treatment for patients with IBD.

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial.

In his ‘Early Dermatology Practice Pearls’ presentation, Dr. Song described tips for dermatologists. In this interview segment, he continues this discussion.

Findings from the phase 1 study informed the clinical development program for GP40141 as a biosimilar treatment for ITP, demonstrating pharmacodynamic similarity to reference romiplostim.

SB16, a denosumab biosimilar, demonstrated pharmacokinetic and pharmacodynamic comparability with reference denosumab in a phase 1 trial in healthy male adults.

Samsung Bioepis gains FDA interchangeability designation for its ranibizumab (Lucentis) biosimilar, ranibizumab-nuna (Byooviz), in the treatment of wAMD, macular edema following RVO, and mCMV

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

New research highlights the potential health risks associated with using smokeless tobacco, including anemia, hypertension, and chronic kidney disease.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’